POST Online Media Lite Edition



 

Medtronic to acquire HeartWare in $1.1 billion deal

Staff writer |
Medtronic will acquire HeartWare in a transaction valued at approximately $1.1 billion. Medtronic will commence a tender offer for all outstanding shares of HeartWare common stock for $58.00 per share, in cash.

Article continues below






The boards of directors of both Medtronic and HeartWare have unanimously approved the transaction. The acquisition is expected to close during Medtronic's second fiscal quarter ending October 28, 2016, subject to the satisfaction of customary closing conditions.

Medtronic's acquisition of HeartWare will expand Medtronic's portfolio of diagnostic tools, therapies and services for patients suffering from heart failure, aligning with Medtronic's Mission of alleviating pain, restoring health and extending life, and is in line with the Company's strategy to surround the physician with innovative products while focusing on patients and disease states.

The addition of HeartWare's innovative portfolio adds to our expanding portfolio of diagnostics, therapeutics and services that address heart failure patients," said Mike Coyle, executive vice president and president of the Cardiac and Vascular Group at Medtronic.

"Medtronic is the worldwide leader in cardiovascular device technologies. Its expansive expertise in the development of implantable systems and battery technologies, patient monitoring, manufacturing, global regulatory policy and commercialization should help accelerate the development and introduction of our innovative pipeline products, and will expand access to our therapies and offerings to the sizeable heart failure population," said Doug Godshall, president and chief executive officer, HeartWare.


What to read next

Medtronic to acquire Covidien for $42.9 billion
Medtronic to return $5 billion to shareholders
Medtronic to acquire Twelve for $458 million